| Identification | Back Directory | [Name]
CMX-2043 | [CAS]
910627-26-8 | [Synonyms]
LIPEA
LIP-EA
CMX-2043
R-LIP-EA-OH
CMX2043,CMX 2043
L-Alanine, N-[5-(3R)-1,2-dithiolan-3-yl-1-oxopentyl]-L-α-glutamyl- | [Molecular Formula]
C16H26N2O6S2 | [MOL File]
910627-26-8.mol | [Molecular Weight]
406.517 |
| Chemical Properties | Back Directory | [Boiling point ]
775.7±60.0 °C(Predicted) | [density ]
1.316±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
3.39±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
CMX-2043 is a novel analogue of α-Lipoic Acid.html" class="link-product" target="_blank">α-Lipoic Acid (HY-N0492). CMX-2043 is effective in antioxidant effect, activation of insulin receptor kinase, soluble tyrosine kinase, and Akt phosphorylation. CMX-2043 shows protection against ischemia-reperfusion injury (IRI) in rat model[1][2]. | [in vivo]
CMX-2043 (50-200 mg/kg, 5 mL; p.o.; single dose) reduces myocardial ischemia-reperfusion injury (IRI) as measured by the myocardial infarct to area at risk (MI-AR) ratio and the incidence of arrhythmia[2].
| Animal Model: | Ischemia-reperfusion injury (IRI) model in Sprague Dawley rats[2] | | Dosage: | 50, 100, and 200 mg/kg; 5 mL of normal saline solution containing 2% vanilla extract as flavoring | | Administration: | Oral gavage; single dose; induced IRI 30-60 min after treatment | | Result: | Induced arrhythmia and mortality of rats with reducing the ratio of myocardial infarct to area at risk. |
| [References]
[1] Alan S Lader, et al. CMX-2043 Mechanisms of Action In Vitro. J Cardiovasc Pharmacol. 2016 Sept;68:241-247.
[2] Baguisi A, et al. CMX-2043 Efficacy in a Rat Model of Cardiac Ischemia-Reperfusion Injury. J Cardiovasc Pharmacol Ther. 2016 Nov;21(6):563-569. DOI:10.1177/1074248416640118 |
|
|